Additional file 1: of Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells

2017-04-26T05:00:00Z (GMT) by Benoît Thibault Bertrand Jean-Claude
In vitro inhibition of HOAC viability by carboplatin alone, or in combination with kinase inhibitors. HOACs were treated with a dose range of carboplatin alone or in combination with dose range of Crizotinib, Dasatinib or Gefitinib, based on a ratio of the IC50 of both drugs. Seventy-two hours after treatment, cell viability was determined by a colorimetric assay using SRB. The negative control (no treatment) of each condition corresponds to the 100% cell viability (Mean +/− SEM, n ≥ 3). (PDF 61 kb)